On May 28, 2021, Omeros announced preliminary results from the second cohort of critically ill COVID-19 patients treated with narsoplimab in Bergamo, Italy. These patients were part of the ﾓsecond surgeﾔ of COVID-19 in Italy. Narsoplimab is the companyﾒs lead inhibitor of mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement.